Moonlake Immunotherapeutics Ag
Clinical trials sponsored by Moonlake Immunotherapeutics Ag, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug trial aims to help teens with painful skin condition Results expected Sep 2026 (estimated)
- New hope for psoriatic arthritis sufferers: experimental drug sonelokimab enters final testing phase Results expected Jan 2027 (estimated)
- New drug sonelokimab aims to ease psoriatic arthritis pain Results expected Feb 2027 (estimated)
-
New arthritis drug shows promise in Long-Term safety trial
Disease control By invitation onlyThis study looks at the long-term safety and effectiveness of a drug called sonelokimab for people with psoriatic arthritis. About 1560 adults who finished an earlier study will receive the drug as a shot under the skin. Researchers will track side effects and how well the drug c…
Phase 3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Sep 10, 2026 04:00 UTC
-
New drug sonelokimab aims to ease psoriatic arthritis pain
Disease control OngoingThis study tests a drug called sonelokimab in 960 adults with active psoriatic arthritis who have not used biologic treatments before. The goal is to see if it reduces joint pain and swelling better than a placebo. Participants receive injections over several months, and research…
Phase 3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for HS sufferers: Long-Term drug trial expands
Disease control By invitation onlyThis study looks at the long-term safety and effectiveness of a drug called sonelokimab for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. About 835 adults and teens who completed an earlier sonelokimab study will receive the drug for an e…
Phase 3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug trial aims to help teens with painful skin condition
Disease control OngoingThis study tests a drug called sonelokimab in 35 teenagers aged 12 to 17 with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition that causes painful lumps. The main goals are to see how the drug moves through the body and whether it is safe. Researchers wi…
Phase 3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC